Antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell-directed therapies that target B-cell maturation antigen (BCMA), such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), are also emerging as standard of care regimens in MM and are detailed later in this review, as well as cereblon E3 ligase modulators (CELMoD® agents). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.